{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-107442","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2026-10-07T13:23:58+00:00","discovered_at":"2026-10-07T13:25:00.216705+00:00","generated_at":"2026-10-12T15:57:22.734766+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cadrenal Therapeutics launches formal strategic review, retains Tungsten Advisors to maximize value","bullets":["Cadrenal authorized a formal strategic process to evaluate licensing/sale of assets, partnerships, or business combinations; no timetable or assurance of a transaction.","Cadrenal engaged Tungsten Advisors as exclusive strategic financial advisor and cited strong interest from potential strategic partners.","Pipeline includes CAD-1005, tecarfarin, frunexian, and CAD-2000; CAD-1005 gained FDA alignment on a Phase 3 pathway for heparin-induced thrombocytopenia.","CAD-1005 has FDA Orphan Drug and Fast Track designations and EMA orphan drug status; tecarfarin is Phase 3-ready; frunexian is a Factor XIa inhibitor.","CEO Quang X. Pham said the pipeline has reached clinical and regulatory maturity, citing FDA alignment on CAD-1005's Phase 3 development pathway."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-107442","json":"https://secwatch.observer/filing/0001213900-26-107442.json","markdown":"https://secwatch.observer/filing/0001213900-26-107442.md","text":"https://secwatch.observer/filing/0001213900-26-107442.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390026107442/0001213900-26-107442-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390026107442/ea0307947-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T15:57:22.734766+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}